Citation:Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Abad A, Valladares M, et al 2012
From Cancer Guidelines Wiki
Citation
Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Abad A, Valladares M, et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist 2012;17(1):15-25 Available from: http://www.ncbi.nlm.nih.gov/pubmed/22234633.
Critical appraisals